Form 4: Apellis Pharmaceuticals Executive Reports Stock Sale and RSU Award

Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, reports selling shares to cover tax withholding and receiving a restricted stock unit (RSU) award.

Summary

• On January 17, 2025, Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, sold 2,145 shares of common stock at a price of $29.9582 per share.
• This sale was to cover tax withholding obligations related to restricted stock units.
• Following the transaction, Nicholson directly owns 52,011 shares of Apellis Pharmaceuticals.
• On January 21, 2025, Nicholson was granted 36,426 restricted stock units (RSUs).
• These RSUs vest 25% annually over four years from the grant date, contingent upon continued service.
• Following the grant, Nicholson directly owns 88,437 shares of Apellis Pharmaceuticals.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions. The RSU grant is a positive sign of incentivizing the executive, but the stock sale, even for tax purposes, introduces a slight negative element.

Positives

• The grant of RSUs to the Chief Technical Officer suggests the company is incentivizing long-term performance and retention.

Negatives

• The sale of shares by an executive, even for tax purposes, could be perceived negatively by some investors.

Risks

• Executive stock sales, even for tax obligations, can sometimes signal a lack of confidence, although this is not necessarily the case here.

Future Outlook

The vesting schedule of the RSUs (25% annually over four years) indicates a long-term incentive plan for the executive.

Industry Context

Executive compensation through stock options and RSUs is a common practice in the pharmaceutical industry to align management's interests with those of shareholders. These grants are typically tied to performance metrics and vesting schedules to encourage long-term value creation.

Comparison to Industry Standards

• RSU grants are a standard component of executive compensation packages in the biotech and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize RSU grants with similar vesting schedules to incentivize their executives.

Stakeholder Impact

• The RSU grant aligns the executive's interests with those of shareholders, potentially driving long-term value creation.
• The stock sale has a minimal impact on stakeholders.

Key Dates